Table 2 Summary of VTE and Major Bleeding Rates in Trials Comparing Extended-Duration Thromboprophylaxis Strategies in Cancer Patients
From: The potential benefits of low-molecular-weight heparins in cancer patients
Ref. | Cancer | Patients, N | Drug | VTE Detection | VTE, % | Bleeding*, % |
|---|---|---|---|---|---|---|
[48] | Gastrointestinal, genitourinary, gynecological | 167 | Enoxaparin 40 mg SC 6--10 days plus placebo 19--21 days | Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, pulmonary angiography | 12 | 3.6 (minor) 3.6 (major) |
| Â | Â | 165 | Enoxaparin 40 mg SC 25--31 days | Â | 4.8 | 4.7 (minor) 5.1 (major) |
[49] | Abdominal (all patients)†| 178 | Dalteparin 5,000 IU OD plus GCS for 7 days | Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, spiral computerized tomography, autopsy | 16.3 | 0.9 (minor) 1.8 (major) |
| Â | Â | 165 | Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days | Â | 7.3 | 1.5 (minor) 0.5 (major) |
[50] | Abdominal cancer sub-group | 198 total | Dalteparin 5,000 IU OD plus GCS for 7 days | Â | 19.6 proximal DVT: 10.4 | Not reported |
| Â | Â | Â | Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days | Â | 8.8 proximal DVT: 2.2 | Â |